Actuate Therapeutics, Inc. · NASDAQ:ACTU
BIOS ADVISORS GP, LLC reported a 52.40% stake in Actuate Therapeutics, Inc. (Schedule 13D/A)
Event May 22, 2025 · Filed May 27, 2025
BIOS ADVISORS GP, LLC reported a 52.40% stake in Actuate Therapeutics, Inc., 10,048,403 shares, with active intent on May 22, 2025. Filed May 27, 2025 (Schedule 13D/A).
- Stake
- 52.40%
- Shares
- 10,048,403
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 24 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOS FUND I, LP | 2.70% | 525,797 |
| BIOS FUND I QP, LP | 1.60% | 307,538 |
| BIOS FUND II, LP | 1.60% | 308,211 |
| BIOS FUND II QP, LP | 5.10% | 1,006,788 |
| BIOS FUND II NT, LP | 0.70% | 134,776 |
| BIOS FUND III, LP | 2.00% | 383,791 |
| BIOS FUND III QP, LP | 12.80% | 2,506,667 |
| BIOS FUND III NT, LP | 2.10% | 404,814 |
| BP DIRECTORS, LP | 0.60% | 116,801 |
| BIOS ACTUATE CO-INVEST I, LP | 1.50% | 300,749 |
| BIOS ACTUATE CO-INVEST II, LP | 10.70% | 2,094,650 |
| BIOS ACTUATE CO-INVEST III, LP | 2.90% | 573,394 |
| BIOS CLINICAL OPPORTUNITY FUND, LP | 6.40% | 1,259,427 |
| BIOS 2024 CO-INVEST, LP | 0.60% | 125,000 |
| BIOS EQUITY PARTNERS, LP | 4.80% | 950,136 |
| BIOS EQUITY PARTNERS II, LP | 8.90% | 1,750,524 |
| BIOS EQUITY PARTNERS III, LP | 30.40% | 5,963,316 |
| BIOS EQUITY COF, LP | 7.10% | 1,384,427 |
| CAVU MANAGEMENT, LP | 44.00% | 8,663,976 |
| BIOS CAPITAL MANAGEMENT, LP | 51.00% | 10,048,403 |
| CAVU ADVISORS, LLC | 44.00% | 8,663,976 |
| BIOS ADVISORS GP, LLC | 52.40% | 10,048,403 |
| LESLIE W. KREIS | 44.40% | 8,733,351 |
| AARON G.L. FLETCHER | 51.30% | 10,109,376 |